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1. Rationale for evaluating metformin  
 
The current standard-of-care (SOC) for men presenting with high-risk locally advanced or metastatic 
prostate cancer (CaP) includes long-term androgen deprivation therapy (ADT), a treatment 
associated with metabolic dysfunction, including insulin resistance, hyperglycaemia and obesity. 
Over 50% who receive long-term ADT develop a form of metabolic syndrome, thus potentially 
increasing their risk of cardiovascular morbidity and mortality.(1) The median overall survival for this 
patient population is now almost 6 years The need to mitigate the debilitating effects of prolonged 
ADT is increasingly relevant.  
 
Metformin has proven benefit in that setting. In non-diabetics the incidence of diabetes is lowered 
and adverse metabolic effects of ADT, including hyperinsulinaemia and dyslipidaemia are 
reduced.(2) In diabetics, metformin decreases myocardial infarction risk and prolongs survival.(3)  
 
These effects may be explained by the activation of Adenosine Monophosphate Activated Kinase 
(AMPK) which inhibits fatty acid synthesis, reducing levels of cholesterol, LDLs and triglycerides. 
Metformin also decreases platelet-aggregation factor 1, other vascular adhesion molecules and 
CRP.(4, 5) Metformin has anti-neoplastic properties, possibly explained by pre-clinical data showing 
that cancer progression is linked integrally with metabolic modulators.(6) Modification of this 
process by metformin has the potential to impact on prostate-cancer specific survival.(7, 8) 
 
Metformin reduces hyperinsulinaemia, which promotes cancer metastasis, growth, and treatment 
resistance.(9) In prostate cancer models, insulin increases mRNA and protein expression of 
steroidogenic enzymes, up-regulating intracellular testosterone levels and androgen receptor (AR) 
activation.(10) By reducing hyperinsulinaemia, metformin can influence multiple other cancer 
pathways including insulin-like growth factor (IGF) and PI3K-AKT / AR signalling, both of which are 
associated with prostate cancer progression and castrate resistance. Metformin also exerts an anti-
proliferative effect via the inhibition of mTOR and may target cancer stem cells and also epithelial to 
mesenchymal transition, thereby inhibiting metastatic progression (12).  
 
Cancer outcomes in diabetic men receiving metformin provide epidemiological evidence of anti-
cancer effect. A meta-analysis of 9,186 men with diabetes and CaP, showed metformin decreased 
biochemical recurrence and improved overall survival.(13)  
 
In response to supporting pre-clinical, clinical and epidemiological evidence of anti-cancer effect, 
trials are now evaluating metformin in lung, breast, pancreatic and ovarian cancer. Encouraging non-
randomised phase II data in castrate resistant CaP demonstrated 36% of patients treated with 
metformin were progression free at 3 months. When compared with baseline values, the PSA 
doubling time was prolonged in 52%, and overall clinical benefit was observed in 46%.(14, 15). 
Ongoing trials in CaP include the Metformin Active Surveillance Trial (MAST), recruiting men with 
low-risk CaP (NCT01864096) and trials adding metformin to abiraterone or docetaxel in the castrate 
resistant setting (NCT01796028, NCT01677897). To our knowledge, there are no ongoing or planned 
trials that will evaluate metformin in men with high-risk locally-advanced or metastatic CaP newly 
commencing long-term ADT.  
 
 
2. Evaluating metformin in the STAMPEDE trial 
 
The ongoing STAMPEDE trial evaluates whether adding therapies to the SOC improves survival in 
men with high-risk localised or metastatic (M1) CaP. By Jun-2016, more than 8,000 consenting men 
at >100 centres in the UK and Switzerland had joined the trial platform which, through using a multi-
arm, multi-stage (MAMS) design, will undertake 9 randomised comparisons.(Figure 1) STAMPEDE is 
in a unique position to address two new and important questions: can the anti-diabetic drug 
metformin be repurposed to mitigate ADT related metabolic dysfunction and can it improve survival 
in CaP patients?  
 
 
The “metformin comparison” will compare SOC plus metformin (new research arm K) to the current 
SOC (control arm A). For inclusion men must be non-diabetic (HbA1c<6.5%, equivalent to 
<48mmol/ml) and meet a more stringent renal cut-off than currently used in the trial (Creatinine 
clearance >60mls/min). Allocation will be 1:1, to control or research arm K. Currently, eligible 
newly-diagnosed M1 patients can also be allocated to receive prostate RT (arm H). Future MAMS 
trial principles for the metformin comparison are different from hitherto: overall survival will be 
used as both the intermediate and definitive primary outcome measure. Failure-free survival (used 
in other comparisons as the intermediate primary outcome measure) is driven predominantly by PSA 
failure and therefore was judged not to be appropriate in determining metformin benefit. The drug 
will be continued throughout long-term ADT and past the FFS event. Approximately 1800 patients 
will be required (included approximately 1200 metastatic patients) to achieve 85% power to detect a 
20% relative improvement in overall survival at the final efficacy stage. Metabolic parameters 
evaluated will include BMI, HbA1c, fasting glucose and lipid profile and any new manifestation of 
cardiovascular disease or diabetes mellitus.  
 
 
3. Challenges and considerations 
 
:: Tolerability 
Metformin is well-tolerated and ongoing trials evaluating its use in non-diabetic men report 
discontinuation rates due to toxicity to be low (~4%). Lactic acidosis, the most serious toxicity, is very 
rare and may be due to underlying diabetes and not metformin treatment. This is supported by a 
meta-analysis demonstrating comparable rates of lactic acidosis in untreated diabetic patients 
compared to those treated with metformin.(16)  
 
:: Optimal duration of treatment 
Metformin can be safety added to other treatments currently used in CaP and, as several of these 
involve co-prescribed steroids, addition of metformin may help counteract the steroid-induced 
hyperglycaemia. Metformin will be continued alongside long-term ADT and given in addition to all 
subsequent treatments. Men with M0 disease at trial entry will receive metformin for 3 years after 
randomisation or until 12 months after the last administration of a LHRH analogue, whichever is 
longer. Men with M1 disease will have life-long therapy provided it is tolerated and safe. The long-
term duration of metformin administration for anti-cancer testing is guided by epidemiological 
evidence showing that it reduces the risk of CaP progression when it is given for 3 or more years.(17)  
 
:: Feasibility  
As a generic, low-cost drug, if shown to be beneficial, metformin could have an impact in both high- 
and low-resource health systems. Taken together with its low-toxicity profile, this means a smaller 
relative improvement is likely to be clinically significant. However, the absence of industry support 
means the acquisition of data is dependent on academic-led studies, which are required to be large 
in order to have the sufficient power to detect a smaller difference. Trial platforms such as 
STAMPEDE which evaluate multiple therapeutic approaches can attract both industry and charitable 
support and accrue at a sufficient rate necessary to address these globally important questions in a 
feasible timescale.  
 
 4. Conclusions 
 
Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to the 
current SOC therapies for CaP. Its use might mitigate the deleterious side-effects of castration and 
also exert an additional anti-cancer effect. It is under investigation in multiple tumour types and with 
the support of the investigators, patients and funders (Cancer Research UK and the UK Medical 
Research Council) it will be incorporated into the STAMPEDE trial platform in summer 2016. This will 
test its true utility as a re-purposed treatment for men with high-risk locally advanced or metastatic 
CaP at first presentation.  
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Figure 1: STAMPEDE accrual activity over time 
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